Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Abrysvo Or Arexvy Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The expansion observed during the historical period was driven by an unfulfilled demand for RSV vaccines, an increasing elderly demographic, the high prevalence of respiratory infections, official regulatory approvals, and greater public health consciousness.
The projected expansion in the coming years is driven by an increasing elderly population, higher rates of RSV-related hospitalizations, wider vaccine guideline updates, enhanced availability of vaccines through healthcare providers, and a stronger emphasis on preventative medicine. Key developments shaping the forecast period encompass a heightened emphasis on RSV prevention, greater uptake of vaccines among older individuals, the broadening of adult immunization initiatives, vaccine distribution in both hospital and community settings, and focused preventive efforts for at-risk groups.
Download A Free Sample Report For Comprehensive Market Insights:
Abrysvo Or Arexvy Market Demand Drivers Creating New Revenue Opportunities
The growing frequency of respiratory syncytial virus (RSV) infections is set to drive the expansion of the abrysvo or arexvy market in the coming period. RSV infections stem from the respiratory syncytial virus, a ubiquitous pathogen that mainly impacts the respiratory system, causing mild cold-like symptoms in most people but posing a risk of severe illness in infants, older adults, and those with weakened immune systems. The heightened occurrence of RSV infections is fueled by the virus’s high transmissibility, seasonal patterns, insufficient herd immunity, and greater vulnerability among groups like the very young and the elderly. Abrysvo addresses the spread of RSV infections by delivering targeted immunizations that safeguard high-risk populations, including seniors and infants, from serious respiratory syncytial virus-associated diseases. For example, in October 2024, data from the Centers for Disease Control and Prevention, a U.S. health protection body, revealed that during the 2024-25 season, the overall hospitalization rate for RSV stood at 3.2 per 100,000 people. Hence, the prevalence of RSV infections is fueling the growth of the abrysvo or arexvy market.
Abrysvo Or Arexvy Market Driver: Impact Of Rising Healthcare Expenditure On The Growth Of The Market
The increase in healthcare spending is anticipated to push the abrysvo or arexvy market forward in the future. Healthcare expenditure represents the financial outlays by governments, private insurers, and individuals within the healthcare system aimed at enhancing and broadening medical services. This rise in spending is attributable to an aging population, progress in medical technology, a higher incidence of chronic diseases, greater demand for medical care, and escalating costs of pharmaceuticals and treatments. Healthcare expenditure benefits abrysvo or arexvy by channeling more funds toward advanced therapeutic options, including biologic treatments. As an illustration, in May 2023, a report from the Office for National Statistics, a UK government agency, noted that healthcare spending in the UK climbed by 5.6% between 2022 and 2023, compared to a 0.9% increase in 2022. The UK’s healthcare expenditure was roughly $317.63 billion (£292 billion) in 2023. Consequently, the rise in healthcare expenditure is propelling the growth of the abrysvo or arexvy market.
Abrysvo Or Arexvy Market Segment Analysis Highlighting Growth Areas
The abrysvo or arexvy market covered in this report is segmented –
1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection
2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation)
3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults
Abrysvo Or Arexvy Market Trends Driving Strategic Industry Expansion
Leading industry players in the abrysvo or arexvy market are concentrating on the creation of cutting-edge solutions, including bivalent prefusion F (RSVpreF) vaccines, aimed at extending protection, improving safety, and targeting high-risk groups. These bivalent RSVpreF vaccines are specifically engineered to induce immunity against both primary RSV subgroups, RSV-A and RSV-B, through the targeting of the prefusion form of the fusion (F) protein, a crucial component for neutralizing antibody responses. As an example, in October 2024, Pfizer Inc., an American pharmaceutical company, secured approval from the U.S. Food and Drug Administration (FDA) for ABRYSVO (RSV Vaccine), a bivalent RSVpreF formulation intended to prevent lower respiratory tract disease in adults aged 18 to 59 who face an elevated risk, thereby broadening its authorized use to the most extensive adult demographic. Furthermore, it continues to be the exclusive RSV vaccine sanctioned for administration to pregnant individuals from 32 to 36 weeks of gestation, offering protection to infants from birth up to six months of age.
Abrysvo Or Arexvy Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the abrysvo or arexvy market are Pfizer Inc., GlaxoSmithKline plc (GSK)
Access The Complete Abrysvo Or Arexvy Market Report:
Abrysvo Or Arexvy Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the abrysvo or arexvy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the abrysvo or arexvy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model